Colombes, France Clinical Trials

A listing of Colombes, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 71 clinical trials
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD). Phase 2: To evaluate the efficacy of efavaleukin alfa in subjects with steroid refractory cGVHD as measured by overall response rate (ORR) at 16 …

H pital Saint Louis
 (6.3 away) Contact site
  • 12 Jun, 2021
  • +28 other locations
Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients 16 Years With Centronuclear Myopathies

There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, PK and PD/preliminary efficacy of a new medicine called DYN101 in patients 16 years of age with CNM caused by mutations in DNM2 or MTM1. The trial will …

Institut de Myologie
 (6.3 away) Contact site
  • 19 Feb, 2021
  • +9 other locations
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the …

Institut Curie
 (6.3 away) Contact site
  • 16 Jun, 2021
  • +67 other locations
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

Patients will be randomized in phase II trials to continue on the same TKI versus one of the alternative treatment approaches. If a patient is not eligible for one of the treatments, he (she) will be randomized between the options for which he (she) is eligible. The trial will start …

H pital Ren Huguenin
 (5.5 away) Contact site
  • 24 Jan, 2021
  • +23 other locations
Universal Cancer Peptide-based Vaccination in Metastatic NSCLC

UCPVAx is a therapeutic vaccine based on the telomerase-derived UCP designed to induce strong TH1 CD4 T cell responses in cancer patients. Three doses of UCPVax (0,25 mg, 0,5 mg and 1 mg) will be tested in this phase I/II study by using Continuous Reassessment Method (CRML) dose escalation design …

measurable disease
recurrent non-small cell lung cancer
large cell carcinoma
St Louis Hospital
 (6.3 away) Contact site
  • 25 Jan, 2021
  • +5 other locations
Acute Ischemic Stroke Interventional Study

To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute ischemic stroke in addition to best emergency standard of care (including fibrinolysis by rtPA with or without added thrombectomy), with a specific focus on hemorrhage, whether clinically symptomatic (NIHSS score + 4 points …

Acticor Biotech
 (7.0 away) Contact site
  • 02 May, 2021
  • +1 other locations
REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

The primary objective of this study is to assess the safety and tolerability of REGN7257 in patients with severe aplastic anemia (SAA) that is refractory to or has relapsed while on standard of care immunosuppressive therapy (IST). An additional primary objective (for Part B only) is to evaluate the clinical …

Regeneron Research Site
 (6.3 away) Contact site
  • 17 Feb, 2021
  • +3 other locations
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

This is an open label, phase I/II clinical trial to evaluate the efficacy and safety of 2 cycles of durvalumab without (Arm A) or with (Arm B) tremelimumab in association with ddMVAC as neoadjuvant therapy in patients with MIUC.

H pital Europ en Georges Pompidou
 (5.8 away) Contact site
  • 25 Jan, 2021
  • +19 other locations
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to <18 years (Cohort A), children aged 2 to <12 years (Cohort B), and infants …

Paris Public Hospitals System; Necker Hospital for Sick Children
 (5.8 away) Contact site
  • 17 Jun, 2021
  • +4 other locations
Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

lung cancer
medullary thyroid carcinoma
cancer chemotherapy
stage iv nsclc
Institut Curie
 (6.3 away) Contact site
  • 15 May, 2021
  • +92 other locations